nalinakshi

consolidating in lower range

NASDAQ:ZYNE   ZYNERBA PHARMACEUTICALS INC
The company is currently in Phase II testing of ZYN002 for treatment of refractory epilepsy and osteoarthritis. It’s also in Phase I testing of ZYN002 for treatment of Fragile X syndrome. ZYN001 is still in preclinical testing for multiple indications as well.

Shares of ZYNE             stumbled at the start of 2017 as the company announced a 2.8 million-share offering priced at $18 to raise cash for its research. But after the dip, investors have piled back in on high hopes that the infusion of cash will yield big results.

The risk here isn’t about sales trends or acquisitions at this point, but simply clinical trial data and typical volatility associated with drug approvals. But if you’re looking to play broader medical marijuana             trends instead of dissecting federal marijuana laws, ZYNE             is a great option – particularly given that its focus on synthetic alternatives may make it more attractive to some consumers or even more effective in its clinical results than naturally grown marijuana
English (IN)
English
English (UK)
Deutsch
Français
Español
Italiano
Polski
Türkçe
Русский
Português
Bahasa Indonesia
Bahasa Melayu
ภาษาไทย
Tiếng Việt
日本語
한국어
简体中文
繁體中文
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out